Actavis Divests In China But Looking For Acquisition; CEO Says Pfizer’s Established Products Division Possible
This article was originally published in PharmAsia News
Executive Summary
Actavis is pulling out of China because its business there is too small and complicated considering the investment of time and capital that could be better spent elsewhere But it could re-enter via a sizeable acquisition, such as Pfizer’s Established Products division.